CLC bio said that its high-throughput sequence analysis infrastructure is expected to empower both OSC’s scientists and OSC’s Genome Network Analysis Service (GeNAS) with a user-friendly and fast workflow to efficiently manage and analyse large quantities of genomics data.
Carsten Daub, director of OSC facility at Riken, said: “It is customary for us to develop our own in-house software that is tailor-made to our needs. However, we were very impressed with the performance and flexibility of CLC bio’s software for a wide range of high-throughput sequence analysis projects and decided that it would be faster and more efficient for us to adopt their enterprise platform.”
David Leangen, CEO of CLC bio Japan, said: “Having such an advanced research center choose our enterprise platform emphasises CLC bio as the leader in high-throughput sequencing analysis solutions. Furthermore, it establishes CLC bio Japan as the major solution provider in the Japanese sequence analysis market.”
Thomas Knudsen, CEO of CLC bio, said: “This agreement accentuates the importance of the Japanese market to CLC bio. To stress our commitment to our operations in Japan, we are already planning further expansions of CLC bio Japan.”